Related Experiment Video
Updated: May 20, 2025

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Dalbavancin Pharmacokinetics in an 18-Month-Old Child Undergoing Extracorporeal Membrane Oxygenation
Alessia Cafaro1, Giammarco Baiardi2,3, Alessio Mesini4
1Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina, Gaslini, Genova, Italy.
Insights
Extracorporeal membrane oxygenation (ECMO) significantly alters dalbavancin pharmacokinetics in children. ECMO increased drug clearance by over twofold, reducing its half-life and potentially impacting treatment efficacy.
Area of Science:
- Pharmacology
- Critical Care Medicine
- Pediatrics
Background:
- Extracorporeal membrane oxygenation (ECMO) provides life support for severe respiratory or cardiac failure.
- Drug pharmacokinetics are frequently altered during ECMO, necessitating therapeutic drug monitoring.
- Maintaining antimicrobial drug concentrations within the therapeutic range is crucial for patient outcomes.
Purpose of the Study:
- To characterize the pharmacokinetic profile of dalbavancin in a pediatric patient undergoing ECMO.
- To assess the impact of ECMO on dalbavancin clearance and half-life.
Main Methods:
- A case presentation describing dalbavancin pharmacokinetics in an 18-month-old child.
- Noncompartmental analysis was used to evaluate drug disposition during and after ECMO.
Main Results:
- ECMO significantly increased dalbavancin clearance, estimated at 2.13 times higher compared to post-ECMO.
- The terminal half-life of dalbavancin was reduced by 52.32% during ECMO (79.13 hours vs. 165.98 hours).
Conclusions:
- ECMO profoundly alters dalbavancin pharmacokinetics, leading to increased clearance and reduced half-life.
- These pharmacokinetic changes may result in suboptimal drug exposure, potentially compromising dalbavancin's efficacy during ECMO support.
Background:
Extracorporeal membrane oxygenation (ECMO) is a life-saving support for patients with severe respiratory or cardiac failure. During ECMO support, the pharmacokinetics of drugs is often affected. Therapeutic drug monitoring of antimicrobial agents ensures drug concentrations remain within the therapeutic range of the pharmacokinetic/pharmacodynamic (PK/PD) target.
Methods:
In this study, we describe the pharmacokinetic profile of dalbavancin in an 18-month-old child during ECMO and after ECMO discontinuation.
Results:
The noncompartmental analysis revealed a notable impact of ECMO on dalbavancin clearance, estimated to be 2.13 times higher during ECMO than after ECMO discontinuation and accounting for a reduction of 52.32% in terminal half-life (79.13 vs 165.98 hours).
Conclusions:
This pharmacokinetic alteration in dalbavancin disposition during ECMO may lead to suboptimal drug exposure, possibly impairing the ability to maintain PK/PD efficacy of dalbavancin over time.
More Related Videos
Related Concept Videos
Two-Compartment Open Model: IV Bolus Administration
The disparity between drug input and the sum of drug transfer rates between...
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Compartment Models: Single-Compartment Model
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
Two-Compartment Open Model: Extravascular Administration
The absorption exponent (ka) indicates the speed at which the drug...
Compartment Models: Two-Compartment Model

